Private equity stopped placing new bets on pet brands, but operators didn't

On May 6, Freshpet reported one of the best quarters it has posted as a public company. Net sales up 13.1% to $297.6M, gross margin at 40.5%, full-year guidance raised. Real operating strength, earned the hard way in a category that got crowded fast. Net income came in at $48.5M against a loss a year earlier.

The biggest single line in that profit was not dog food. It was a $62M gain from selling its minority stake in Ollie, cashed out for $95.5M when Spanish consumer group Agrolimen bought the fresh-food brand in February.

Two weeks later, Freshpet's board took the proceeds and authorized a $150M buyback of its own shares, which the CFO said were trading below intrinsic value.

So a public pet company had a career quarter, and its most profitable move was selling its piece of a hot brand to a strategic acquirer, then buying back its own discounted stock.

One company's capital decisions across a single spring, and they map the entire 2026 exit market. Deals are closing again and the money is real. But the buyers have sorted sellers into two lines. Consumer pet brands, the food, treats, and supplements on the shelf, now exit one way, a sale to a bigger operator. Pet care, the clinics, insurance, and health services behind the animal, can still raise from financial investors. And nobody is taking the third door, a public listing, while the market keeps discounting the best pet operator it has.

Count the deals. We did.

From January 1 through last week we can verify 12 marquee pet transactions.

Instinct Science took AI scribe ScribbleVet in January. February produced four on its own: Cencora folded MWI Animal Health into a $3.5B combination with Covetrus, Nasta acquired FirstMate, Pure Treats bought Primal out of Kinderhook's portfolio, and Agrolimen took Ollie. Bending Spoons signed for Tractive in March. Chewy agreed to buy Modern Animal in April. May brought Golden Pet Brands closing on the Petsource freeze-dry plant, Assisi adding treat brand NAW, and Tractor Supply buying VIP Petcare from PetIQ. June closed with PetVivo's biomaterials merger and Japan's Umios paying about $70M for a majority stake in Malaysia's Pet World International.

Capstone Partners, whose deal tracker captures processes that never get a press release, counted 18 transactions against eight in the prior-year period as of its April data cut, which predates five of the deals above.

Broader net, earlier cutoff, same direction. Capstone called it a welcome change from four years of annually contracting volume, and Carol Frank at BirdsEye, who called 2025 the slowest period of her 15-year M&A career, is now cautiously optimistic. One caveat covers all of it. Doubling off the worst year anyone can remember is a recovery from a trough, not a boom, and some of this year's closings are last year's stalled processes finally signing.

The more useful question is not how many deals. It is who wrote the checks.

Line the buyers up against what they bought and a pattern falls out that the deal count hides.

Every consumer brand and every production asset on the marquee tape went to an operator. FirstMate to a pet food manufacturer. Primal to the company behind PureBites. Ollie to a Spanish consumer group. The Petsource plant to a brand group that wanted the freeze-dry capacity. Pet World International to a Japanese food company.

Widen the net past the marquee deals and our fuller ledger runs to 25 transactions in the same window. Private equity shows up all over the longer list, but only as an add-on buyer, funds bolting acquisitions onto pet companies they already own. Axcel's Nutriment Company bought two more raw-food producers. Trivest's resort group added four boarding sites. EQT's IVC Evidensia added clinics. What no fund did in 2026 is buy a pet brand outright as a new investment, the way BC Partners took a majority of PetLab in early 2025.

Across all 25 deals, that count is zero.

Capstone's April read pointed the same direction from a different angle.

Strategic buyers took 10 of the period's deals, all of them private companies at that point. By July even that needs updating in a way that sharpens the pattern, because Chewy and Tractor Supply, both public, closed vet care deals since. Public or private stopped being the dividing line. Operator or not is the line that holds.

The operators are also telling you they are not done. Central Garden & Pet's CEO said on the Q1 call the company is in several discussions right now and feels quite good about accelerating. That comment reads differently once you notice what Central did in April, handing operating control of its distribution arm to Phillips in a joint venture while keeping 20%. Shedding distribution frees cash and management attention for exactly one job, buying and building brands. Vimian says all four of its verticals are hunting bolt-ons and platforms. Chewy management, asked in June, kept the door open to more vet care M&A while Modern Animal contributes an expected $70M to this year's sales.

Why operators can pay when funds cannot shows up inside the Modern Animal deal. Chewy expects over $125M in annualized run-rate revenue plus a 15 to 20% lift in net sales per active customer across the combined network. A fund buying Modern Animal gets clinic revenue. Chewy gets clinic revenue plus 100,000 member families pushed into an ecosystem it already monetizes.

There is a second reason the buyers of vet care assets are now retailers and platforms rather than funds, and Ivan Zak gave it to us plainly when we recorded a podcast with him recently. Zak is the veterinarian who built the clinic-workflow software Smartflow and sold it to Idexx, then consulted vet groups through the roll-up boom before founding two ventures of his own: the employee-owned health system Galaxy Vets and the relief-staffing platform Serenity Vet. He spent years pitching Galaxy Vets to private equity, so he has watched consolidation from every seat.

His verdict on the roll-up era: "You could really get money from private equity and then buy clinics at 10x and resell at 26. It's a no-brainer. You don't need to know how to operate that." And on why the new generation of clinic platforms gets bought while the old roll-ups sit: "It's easier to build than to buy and convert." Modern Animal was built, not rolled up. That is what Chewy paid for.

On the marquee brand deals, private equity appears three times. Every time as the seller.

Kinderhook sold Primal. Bansk's PetIQ sold VIP Petcare. Freshpet, playing the financial-holder role in this one respect, cashed out its Ollie stake the moment a strategic showed up.

That is an aging-inventory problem, not a lost appetite. Sponsors formed 66 pet platforms between 2019 and 2022, per the same Capstone report, and those holdings are now past their intended hold periods while LPs push for distributions. Since 2023, sponsors have exited nine pet investments through M&A, and more than half were sponsor-to-sponsor, one fund handing the parcel to another. All of that sits on top of the $45B PitchBook says private equity put into the veterinary sector alone from 2017 through 2022.

The math that built those positions is gone. Most of them were underwritten when leverage was close to free. The fed funds rate averaged just 0.08% in 2021, and even after the spread, all-in buyout debt cost only mid-single digits. That same financing now clears 9 to 9.6% all-in, with direct-lending yields holding near 9 to 10% per StepStone, roughly double the cost of the money that built these positions in the first place.

A leveraged five-year hold at those coupons only pencils if the business grows faster than most pet consumables have grown since 2023. Zak watched the same door close from the inside. He took his own vet platform out to raise "the day when Silicon Valley Bank went down," and in the years since, by his count, essentially no new vet consolidations have been built.

The rotation, though, is more precise than "PE left." Capstone counts three new PE platform deals in pet this year against zero in the same period last year, plus five add-ons.

Small Door Veterinary stacked $55M in equity and debt last July for membership vet care. Lassie, the prevention-first European insurer, raised $75M in February after clearing $100M in ARR. Cascadia's 15 years of deal data explain the destination: animal health commands a 19.7x mean multiple and vet care 17.3x, against 12.6x for consumables. Financial capital did not leave pet. It repriced products and kept paying for care.

So there is a second door after all. It opens for clinics, insurance, and health platforms. It does not open for the brand on the shelf.

There is exactly one pet food brand visibly moving toward a listing anywhere, and the reporting on it is sourced, not filed. Reuters says Open Farm, the Canadian premium brand that just landed in 1,700 PetSmart stores, is preparing a Toronto IPO. The biggest float actually in the pipeline, TPG's Greencross in Australia, was put on hold on market volatility. The only live US pet S-1 belongs to Akston Biosciences, a pre-revenue pet-medicines biotech that has sat in amendments since last fall. No US pet consumables company has filed anything.

The explanation trades on Nasdaq under FRPT. The quarter Freshpet printed in May would be a good quarter in any consumer category, and the stock closed Monday around $54.63, roughly a third below its 52-week high. BofA's July target cut named the fear, Hill's entering fresh dog food.

Here is the part that should worry anyone drafting an S-1. Even marked down, Freshpet is not cheap. It trades at 2.45x enterprise value to revenue, a premium to General Mills at 1.82x, and about 15x EBITDA against the packaged-food set near 10x. The public market is still paying growth prices for the category leader. What it keeps cutting is its estimate of where the category's margins settle once every incumbent piles into fresh. A founder weighing a listing is not being offered Freshpet's business. They are being offered that skepticism, applied to a smaller company, on day one. Against that, a strategic conversation that might value you the way Agrolimen valued Ollie is not a hard call.

The strongest argument against everything above is that the buyers did not change. The sellers did.

Anna Skaya at AniVC told GlobalPETS the companies failing to transact mostly share weak differentiation and high acquisition costs. There is a lot of cash and a shortage of good companies, as a Central Garden executive put it last fall. On this read, the one-door market is partly an optical illusion created by what happened to be for sale, a parade of brands built in the 2020 boom on paid social that no buyer type was going to pay up for.

The floor data leans the same way. Average disclosed pet-sector multiples ran 14.5x from 2022 through 2025, up from 13.4x over the four prior years, per Capstone figures we compiled in March. The compression happened at the top of the market, not across it. That pattern says choosier, not absent.

And smart consumer money is still walking in the entrance. Golden Child, a premium dog food brand incubated at Atomic, the venture studio run by Hims & Hers co-founder Jack Abraham, came out of stealth in April with $37M raised across a seed round and a Series A led by Redpoint.

Its operating co-founders are Hillary Coles, another Hims co-founder, and Quentin Lacornerie, an early Hims VP. Count Joe Spector, a third Hims co-founder who left to build pet telehealth company Dutch, and three of the four people who founded the biggest DTC health company of the last decade, plus one of its early executives, now have bets in pet. Entry capital is not exit capital, and $37M of conviction says nothing about what Golden Child sells for someday. It does say the operators who priced human wellness correctly still think this category's story is early.

Both points deserve real weight, and neither restores optionality for a seller. One choosy buyer type is still a worse market than three eager ones, whatever it says about the assets on the block.

Fewer kinds of bidders changes the physics of every process, including the good ones.

The best consumables companies commanded EBITDA multiples in the mid-20s or higher at the 2021 peak. Frank now puts that tier at mid-teens to low-20s. The median tells it harder. R.L. Hulett's Q1 tracking has reported pet deals at 8.2x EBITDA for sponsor deals and 8.5x for strategics. And closing risk became the real price of admission. In 2024, the last year Cascadia disclosed the figure, just 15% of bank-led pet processes actually closed, the lowest realization rate the bank had ever tracked, per the same March coverage.

The auction logic is unforgiving. Operators bid against other operators only where portfolios overlap, and without financial bidders setting a floor underneath them, advisors say processes now go to whoever offers certainty of close rather than the biggest number, with earnouts doing more of the work in every term sheet. A strategic premium and a strategic discount turn out to be the same number, viewed from opposite sides of the table. The acquirer pays for synergies nobody else can extract, and pays less than they are worth, because nobody else is bidding.

For a decade, built to sell meant built to grow, because there was always another bidder type standing behind the one in front of you. Operators wanted growth, sponsors wanted brand heat, the public market wanted a story. That stack of options is what 2022 killed, and this year's rebound has not resurrected it.

Look at what the 2026 buyers actually paid for. Chewy paid for clinic unit economics that plug into an ecosystem it already runs. Agrolimen paid for a brand and subscriber base it publicly promised to leave intact. Golden Pet Brands paid for freeze-dry capacity. In every case the seller owned something the buyer could not build internally at any sane speed. That is the premium now. A brand a strategic could replicate with 18 months and a budget is negotiating against the buyer's build option, and the build option never pays mid-20s.

Three clocks to watch from here. Whether Open Farm's Toronto listing goes from sourced reporting to a filed prospectus, because one well-priced pet food IPO would crack the second door for every premium brand at the table.

Whether any of the 66 aging sponsor platforms finds a financial buyer at a real multiple, the cleanest test of whether PE's absence from brands is cyclical or structural. And whether Chewy buys again, because the most informed acquirer in pet just told the market its appetite is open.

Capstone expects sponsor selling pressure to strengthen into 2027 as LPs demand liquidity. More motivated sellers are coming either way. The founders who get paid will be the ones holding something an operator cannot build, because for now, the exit door in pet only opens from the inside.

The tape in this piece comes from the M&A ledger we have maintained since February 2025, now 70 verified deals with acquirer, segment, region, deal type, and buyer type on every row.

The free ledger is yours.

For pro members, we took the ledger further. The 2026 Pet M&A Report derives the numbers nobody in the industry has published, starting with the one we kept re-checking because we did not believe it the first time. At the current exit pace, private equity's pet platform backlog takes 22 years to clear, and that is the generous count, treating even one fund selling to another as an exit.

Count only true sales to outside buyers and the runway is longer still. The report covers the full methodology behind that figure, the complete 2026 deal tape, the financing math that broke the old playbook, and what all of it means if you are holding, buying, or building toward a sale. It lands in the pro library alongside this issue.

Access here if you want it, and if you are already pro, it is waiting for you.